Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH3127 in Mild-to-Moderate Ulcerative Colitis
NCT05019742Phase 2Terminated
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitokiren in ulcerative colitis (UC), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Mar 2022; status: terminated.
02
Drugs
sitokiren
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05019742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019742.